Results 281 to 290 of about 3,248,558 (306)

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.

Blood
Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG.   +26 more
europepmc   +1 more source

Susceptibility of broad reactivity nanobodies to resistance mutations in the S2 domain of SARS-CoV-2 predicted by yeast display deep mutational scanning. [PDF]

Front Immunol
Ball CR, Ramage W, Mate R, Hufton SE.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Genetic testing in prostate cancer management: Considerations informing primary care

Ca-A Cancer Journal for Clinicians, 2022
Veda N Giri, Jacob E Berchuck, Mary-Ellen Taplin   +2 more
exaly  

SARS-CoV-2 variants, spike mutations and immune escape

Nature Reviews Microbiology, 2021
William T Harvey, Alessandro Maria Carabelli, Benjamin C Jackson   +2 more
exaly  

The implications of IDH mutations for cancer development and therapy

Nature Reviews Clinical Oncology, 2021
Christopher J Pirozzi, Hai Yan, Hai Yan
exaly  

Epithelial ovarian cancer: Evolution of management in the era of precision medicine

Ca-A Cancer Journal for Clinicians, 2019
Stephanie Lheureux, Marsela Braunstein, Amit M Oza   +2 more
exaly